TiumBio Receives Approval for Phase 2a Clinical Trial Plan of Endometriosis Treatment
[Asia Economy Reporter Minji Lee] Tium Bio announced on the 24th that it has received approval for the Phase 2a clinical trial plan of the endometriosis treatment TU2670 in Ukraine.
Hot Picks Today
"Buy on Black Monday"... Japan's Nomura Forecasts 590,000 for Samsung, 4 Million for SK hynix
- "Not Everyone Can Afford This: Inside the World of the True Top 0.1% [Luxury World]"
- "Plunged During the War, Now Surging Again"... The Real Reason Behind the 6% One-Day Silver Market Rally [Weekend Money]
- "We're Now Earning 10 Million Won a Month"... Semiconductor Boom Drives Performance Bonuses at Major Electronic Component Firms
- Experts Are Already Watching Closely..."Target Stock Price 970,000 Won" Now Only the Uptrend Remains [Weekend Money]
The company stated, "The Phase 2a clinical trial of TU2670 will be conducted in multiple European countries (Ukraine, Russia, Italy, Poland, Czech Republic) to improve patient enrollment rates," and added, "We plan to disclose the clinical trial plan applications for Italy, Poland, and the Czech Republic in accordance with disclosure guidelines in the future."
This content was produced with the assistance of AI translation services.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
